Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). …

To identify common genetic variants that contribute to lung cancer susceptibility, we conducted
a multistage genome-wide association study of lung cancer in Asian women who never …

Background The US Preventive Services Task Force (USPSTF) recommends lung cancer
screening among individuals aged 55–80 years with a 30 pack-year cigarette smoking history …

Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity
when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-…

Background Novel adjuvant strategies are needed to optimise outcomes after complete surgical
resection in patients with early-stage non-small-cell lung cancer (NSCLC). We aimed to …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …

Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free …

Coronavirus disease 2019 (COVID-19) is mainly an infectious disease of the respiratory system
transmitted through air droplets, and pulmonary symptoms constitute main presentations …

Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective
oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-…

Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …